Skip to main content
PLOS One logoLink to PLOS One
. 2024 Mar 29;19(3):e0300777. doi: 10.1371/journal.pone.0300777

The psychological burden of NMOSD – a mixed method study of patients and caregivers

Darcy C Esiason 1, Nicole Ciesinski 2, Chelsi N Nurse 2, Wendy Erler 3, Tom Hattrich 3, Ankita Deshpande 3, C Virginia O’Hayer 1,*
Editor: Teresa Juárez-Cedillo4
PMCID: PMC10980246  PMID: 38551980

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disorder of the central nervous system with common symptoms of rapid onset of eye pain, loss of vision, neck/back pain, paralysis, bowel and bladder dysfunction and heat sensitivity. The rare, unpredictable, and debilitating nature of NMOSD constitutes a unique psychological burden for patients and their caregivers, the specific nature and extent of which is not yet known. This mixed methods study, informed by both quantitative and qualitative data collected via self-report measures, focus groups, and in-depth interviews, aims to investigate and understand the psychological burden of patients with NMOSD and their caregiver/loved ones, so as to inform a specialized intervention. 31 adults living with NMOSD and 22 caregivers of people with NMOSD in the United States and Canada, recruited from NMOSD patient advocacy groups, social media groups, and through word of mouth from other participants, completed a battery of standardized self-report measures of anxiety, depression, trauma, cognitive fusion, valued living, and coping styles. Semi-structured focus group sessions were conducted via HIPAA-compliant Zoom with 31 patients, and separate focus groups were conducted with 22 caregivers. A subset of these samples, comprised of 16 patients and 11 caregivers, participated in individual semi-structured interviews, prioritizing inclusion of diverse perspectives. Descriptive statistics and bivariate correlations were run on quantitative self-report data using SPSS [Version 28.0.1]; data were stored in REDCap. Reflexive thematic analysis was employed regarding qualitative individual interview data. The majority of patients reported experiencing anxiety, depression, cognitive fusion, over-controlled coping, and lack of values-based living. Caregivers also reported heightened anxiety, cognitive fusion, and over-controlled coping, although they did not endorse clinically significant depression. Patient and caregiver degree of anxiety and of overcontrolled coping were both strongly positively correlated, likely affecting how both parties manage NMOSD-related stressors, both individually and as a dyad. Patients reported more anxiety, depression, psychological inflexibility, and lack of values-based living, compared with caregivers. Patient and caregiver narrative themes included mistrust of medical professionals, lack of support immediately following diagnosis, changes in relationships, deviation from values-based living, internalization of feelings, and avoidant coping strategies to manage the psychological burden of NMOSD. A novel mental health intervention targeting the specific psychological burden of life with NMOSD is proposed.

Introduction

Neuromyelitis optica spectrum disorder (NMOSD), is an inflammatory disorder of the central nervous system, characterized by recurrent attacks of inflammation and damage in the optic nerves and spinal cord. Despite availability of newer diagnostic tests [1] and consensus regarding diagnostic criteria [2], misdiagnosis with Multiple Sclerosis (MS) and subsequent iatrogenic treatment that exacerbates an NMOSD attack, is often part of the diagnostic history of adults with NMOSD [3, 4]. NMOSD attacks are unpredictable in nature and cause rapid onset of eye pain or blindness, limb weakness/numbness/paralysis, pain, loss of bowel and bladder control, and prolonged nausea/vomiting/hiccups [5]. NMOSD is about 8 times more prevalent among women (9:1 ratio among individuals who are anti-AQP4 seropositive) and among individuals with African, Asian, Pacific Island, Polynesian or Caribbean genetic ancestry [6].

The rare, unpredictable, debilitating nature of NMOSD creates a unique psychological burden on patients and their loved ones, the specific nature and extent of which is largely unknown. While the empirical literature to date, a summary of which follows, consistently documents depression, anxiety, pain, and sleep concerns, there is not currently a sufficient depth of knowledge required in order to address the psychological burden of NMOSD via an effective mental health intervention. In addition to general knowledge about the presence of anxiety, for example, detailed understanding is needed regarding the nature, context, degree, and impact of anxiety on the lives of patients and their caregiver/loved ones. The present study is intended to deepen our understanding of the extent and nature of this phenomenon, including as experienced by caregiver/loved ones. It is important to determine which aspects of psychological burden impact patients, caregivers, or both, and to what extent, as well as what events and context associated with increased burden. Our ultimate goal is to inform and inspire an intervention to address the unique psychological burden of NMOSD.

Depression and anxiety are common among individuals with NMOSD, with 30% to 50% endorsing clinically significant depressive symptoms [710] and 33% endorsing anxiety [11]. NMOSD patients are twice as likely to experience Major Depressive Disorder and high suicidal risk, as compared with patients with Multiple Sclerosis [9]. Among individuals with NMOSD, elevated anxiety is predictive of poor sleep quality [12] and poor overall quality of life [1215].

Pain, sexual dysfunction, and stigma substantially impact emotional well-being and quality of life among people with NMOSD [16]. Chronic pain affects over 80% of NMOSD patients [17], including in the absence of recent relapse [18]. Pain severity is the strongest negative predictor of quality of life, and the most common symptom reported by NMOSD patients [18]. Three-quarters of men and women with NMOSD report sexual dysfunction, specifically reduced libido, decreased orgasm, and erectile dysfunction [19, 20]. Further contributing to the psychological burden, 60% of patients reported being affected by NMOSD-related stigma. Embarrassment due to physical limitations, perceived exclusion, avoidance/ostracism, and blame for their illness were deemed the most impactful manifestations of stigma, correlating with poor quality of life [21].

The psychological impact of NMOSD on caregivers and loved ones remains under-studied to date. A fifth of loved ones of NMOSD patients were found to be experiencing mild to moderately severe depressive symptoms [22]. Partners described pressure to take on new roles both inside and outside of the home during NMOSD relapses, limiting hobbies and activities to prioritize the patient’s health, and both male and female partners reported challenges related to gender role shift [23].

The psychological burden of NMOSD is frequently mentioned by patients and loved ones in online forums, personal blogs, sub Reddits and social media groups. The inclusion of patient and caregiver voices allows a rich picture of the lived experience of people living with NMOSD and their caregivers. Patients and loved ones often discuss anxiety—particularly regarding future relapses [24, 25], difficulty obtaining a correct diagnosis [26] including misdiagnosis with MS—resulting in medical intervention that served to exacerbate NMOSD [27, 28], physical disability, emotional and financial impact on relationships [29, 30], and dealing with an “invisible illness” [31, 32] as central components of life with NMOSD.

Empirical literature and patient media perspectives suggest a significant unique psychological burden associated with diagnosis of NMOSD, although the full nature and extent of this burden is unclear, including as it pertains to caregivers. There is a clear need to develop a comprehensive understanding of this experience, both from patient and caregiver perspectives, so as to develop a targeted coping skills intervention to effectively meet this burden. This mixed methods study, using a combination of quantitative psychometric test data and qualitative data derived from focus groups and in-depth interviews, aims to identify and categorize salient features of the psychological burden specific to NMOSD to best inform effective intervention approaches.

Materials and methods

Participants

All participants completed informed consent prior to enrollment in this mixed methods study. The study protocol, as well as all participant-facing materials, were approved by the Thomas Jefferson University Institutional Review Board prior to study administration. Thirty-one patient participants were recruited via private NMOSD patient advocacy groups (Sumaira Foundation, Connor B. Judge Foundation, Guthy-Jackson Foundation), patient social media groups, and through word of mouth from other participants. Twenty-two caregiver participants were primarily recruited by requesting participation from patient participants. Caregivers were defined as anyone serving in a close supportive role for the patient, and could include spouses, partners, adult children, siblings, parents, close friends, other close family members. Inclusion criteria for the study were: (1) 18 years or older, (2) living with a diagnosis of NMOSD or caring for a loved one with NMOSD, (3) able to understand English, and (4) Canadian or US citizen. There were no exclusion criteria. Patient and caregiver participants were compensated via $150 gift card for completion of self-report measures and participation in a focus group, consistent with NIH guidelines to provide reasonable compensation for participant’s time, particularly in the context of rare diseases with limited populations [3335], and comparative with recent focus groups and interviews in the context of NMOSD [36].

Individual interviews occurred concurrently with focus groups after the completion of the first focus group. For the interviews, purposive sampling was used to ensure representation of racial and ethnic diversity, in attempts to approximate a sample representative of the larger population of NMOSD patients. Focus group participants who identified as members of diverse racial/ethnic groups were invited to participate in individual interviews, to ensure inclusion and representation of their voices. Similarly, male participants were also invited to participate in individual interviews. Both patient and caregiver participants were compensated via $150 gift card for completion of self-report measures and participation in an individual interview.

Measures

Prior to participation in focus groups, patients and caregivers completed a demographics survey as well as psychometric measures of anxiety (BAI), depression (BDI-II), cognitive fusion (CFQ-13), valued living (VLQ), psychological flexibility (AAQ-II), trauma history (ACEs) and coping styles. Finally, participants completed items assessing openness to treatment.

Anxiety

Anxiety symptoms were assessed using the Beck Anxiety Inventory (BAI) [37], a 21-item self-report measure assessing symptoms of anxiety over the past week. Sample items include “nervous” and “frightened”, with answer options ranging from 0 (not at all) to 3 (severely) and total scores ranging from 0–63, with a higher score indicating higher levels of anxiety symptoms. Scores of 8 or above suggest clinically relevant anxiety. The BAI demonstrated excellent internal consistency in the full sample (α = .92).

Depression

Depressive symptoms were measured by the Beck Depression Inventory II [38]. This 21-item self-report measures depressive symptoms over the past 2 weeks. The BDI-II assesses affective, cognitive, behavioral, and somatic symptoms of depression and has good construct validity [38]. Item scores range from 0–3. Possible total scores range from 0–63, with higher scores indicating higher levels of depressive symptoms. Scores of 17 or above suggest clinical depression. The BDI-II demonstrated excellent internal consistency in the full sample (α = .90).

Cognitive fusion

Cognitive fusion was measured by the Cognitive Fusion Questionnaire (CFQ-13) [39], a 13-item self-report assessment of the degree to which one is “hooked” or “fused” to one’s thoughts. Responses range from 1 (not true at all) to 7 (always true). Possible scores range from 13–91, with higher scores indicating higher levels of cognitive fusion. Scores of 34 or above suggest clinically relevant cognitive fusion. The CFQ demonstrated good internal consistency in the present sample (α = .82).

Psychological flexibility

Psychological flexibility was assessed using the Acceptance and Action Questionnaire (AAQ-II) [40], a 7-item measure of psychological inflexibility/experiential avoidance, with higher scores indicating greater inflexibility. Scores of 24 or above suggest clinically relevant psychological inflexibility. The AAQ demonstrated good internal consistency in the full sample (α = .89).

Valued living

Valued living, a construct similar to purpose in life, measuring the degree to which one is living according to their chosen value was measured by the 10-item Valued Living Questionnaire [41]. The VLQ demonstrated acceptable internal consistency for rated importance (α = .73) and good internal consistency for past-week practice of value (α = .81).

Trauma history

History of trauma was measured by the Adverse Childhood Experience Questionnaire (ACEs) [42], a 10-item questionnaire assessing 10 categories of abuse, neglect, and household dysfunction, in childhood. Scores of 4 or above suggests clinically significant range of adverse childhood experiences. The ACE demonstrated acceptable internal consistency in the full sample (α = .76).

Coping style

Coping style, in particular whether the respondent leans toward overcontrolled coping or undercontrolled coping, was measured by the Styles of Coping Word-Pairs [43], a 47-item forced-choice measure of overall personality style. It demonstrated good internal consistency in the present sample (α = .85).

Procedures

Focus groups were conducted via HIPAA-compliant Zoom teleconferencing platform, with video on. Focus groups lasted 60 minutes, were offered at convenient times (including evenings), and were facilitated by licensed clinical providers (CVO’H, DCE). Patient and caregiver focus groups were conducted separately, to ensure patient privacy, and so that caregivers felt free to engage in an honest discussion about challenging aspects of their role. Focus groups required a minimum of 3 and a maximum of 12 participants, to ensure adequate variety of responses and time for each member to participate.

Each focus group began with a vote via show of hands (or raised hand Zoom feature) regarding which topics were of interest and relevance to members. Topics were derived from review of empirical and patient voices literature as well as literature regarding mental health concerns among other chronic neurological conditions. Additional questions were included regarding the impact of the COVID-19 pandemic. Each group ended with the open-ended invitation to offer other information that facilitators may not have known to ask.

Individual interviews lasted from 45–60 minutes and were also conducted via HIPAA-compliant Zoom, by the same research team members, and were recorded for transcription. These semi-structured interviews were informed by themes and content emerging from the focus group component of this study, as well as by detailed review of both the empirical literature regarding psychosocial stressors associated with NMOSD and of patient-driven data as described earlier. One caregiver individual interview took place in written format only, as the caregiver was deaf and did not feel comfortable participating via phone or Zoom. In efforts to include her valuable perspective, she was offered participation via written response to the interview prompts.

Data analysis

Quantitative analyses

SPSS [Version 28.0.1] statistical software was used to conduct all quantitative analyses. Data were stored in REDCap. Total scores and clinical cutoffs were calculated from the raw psychometric test data. Descriptive statistics were run on all demographic and psychological variables. All continuous variables were assessed for normality and linearity. Results of the Kolmogorov Smirnov and Shapiro-Wilk Tests demonstrated that the BAI and the coping style questionnaire total scores were non-normally distributed in the patient sample, whereas the coping style questionnaire and the ACE total scores were non-normally distributed in the caregiver sample. Thus, bootstrapping was implemented in all inferential analyses to adjust for non-normal distributions. Bivariate correlational analyses were run assessing the relationships among all psychological variables in the independent patient and caregiver samples. As the patient sample was 90% (n = 27) female, gender differences across psychological variables were probed only in the caregiver sample (52.4%, n = 11 female) with t-tests. Additionally, bivariate correlations and t-tests were run on paired patient-caregiver data to assess the relationships and differences between patients and their caregivers across the psychological variables.

Qualitative analyses

Semi-structured focus group sessions were conducted via HIPAA-compliant Zoom with 31 patients, and separate focus groups were conducted with 22 caregivers. A subset of these samples, comprising 16 patients and 11 caregivers, participated in individual semi-structured interviews, prioritizing inclusion of diverse perspectives.

Focus group data were analyzed through classical content analysis. A priori codes were developed prior to focus groups based on thorough review of both empirical and patient-based literature as described in the Introduction. During focus groups, an assistant moderator tallied the frequency of participants’ use of a particular code. After focus groups, researchers used audio files of focus groups to assign semantic data to each code. Focus group data informed the development of semi-structured interview guides for individual interviews. Distinct interview guides were developed for the patient interviews and for the caregiver interviews. Interviewers also allowed for open-ended discussion as guided by the patient and caregiver’s prior answers and topics of interest. Individual interviews began after the first focus group concluded.

Individual interviews were recorded, transcribed, and analyzed according to the 6 steps of reflexive thematic analysis [44]: (1) familiarizing oneself with the data, (2) generating codes, (3) constructing themes, (4) reviewing potential themes, (5) defining and naming themes, and (6) producing the report [44]. One interview was conducted by writing only, as the spouse-caregiver is deaf.

Individual interviews were transcribed by two transcriptionists in the Thomas Jefferson University Department of Public Health. Investigators (DCE & CVO’H) read each transcript to familiarize with the data. Researchers developed two codebooks–one for patient interviews and one for caregiver interviews–with both deductive and inductive input, including codes derived from investigator clinical experience with rare disease psychology, review of empirical literature, codes derived from analysis of the focus groups, and codes generated from initial review of individual interviews. Using a roundtable approach, investigators (DCE & CVO’H) manually mapped themes as they were conceptualized from the data. Investigators (DCE, CVO’H, CNN, NKC and 3 graduate students) then refined the codebook and continued to review themes before a second roundtable was hosted to identify the overall narratives in the analysis.

Results

Psychometric test data—patients

Thirty out of 31 patient participants completed a demographics survey. One patient failed to turn in any questionnaire data. Twenty-two caregivers completed a caregiver version of the demographics survey. Summary statistics describing the focus group sample are listed in Table 1. See S2 Data.

Table 1. Sociodemographic characteristics of participants in focus groups.

Baseline characteristics Patients Caregivers
n % n %
Gender
 Female 27 90 11 50
 Male 3 10 11 50
Racial/Ethnic Identity
 Caucasian 21 70 14 64
 Hispanic 4 13 1 5
 Asian American/Pacific Islander 3 10 1 5
 African American/Black 2 6.7 3 14
 Other 0 0 1 5
 Chose Not to Answer 0 0 1 5
AQP4 Positive 80 24 n/a n/a
Hospitalization due to NMOSD*
 Lifetime 24 80 19 85
 Past Year 7 23 5 20
 Past 1–3 Years 0 0 2 10
 Past 3–5 Years 8 29 8 35
 Over 5 Years Ago 9 26 3 22
Caregiver Relationship
 Spouse/Partner n/a n/a 8 36
 Parent n/a n/a 5 23
 Adult Children n/a n/a 4 18
 Sibling n/a n/a 3 14
 Cousin n/a n/a 1 5

N = 30 for patients, 22 for caregivers.

*Reflects the number and percentage of loved ones of caregivers who reported hospitalization due to NMOSD.

Sixteen patients and eleven caregivers who participated in focus groups were invited to participate in individual interviews, prioritizing inclusion of diverse racial/ethnic and gender presentations. Sample summary statistics for individual interview participants are described in Table 2.

Table 2. Sociodemographic characteristics of participants in individual interviews.

Baseline characteristics Patient Caregivers
n % n %
Gender
 Female 13 81 5* 45
 Male 3 19 6 55
Racial/Ethnic Identity
 Caucasian 10 63 8 73
 Hispanic 1 6 1 9
 Asian American/Pacific Islander 2 13 1 9
 African American/Black 3 19 1 9
 Other 0 0 0 0
 Chose Not to Answer 0 0 0 0
Caregiver Relationship
 Spouse/Partner n/a n/a 6* 54
 Parent n/a n/a 3 27
 Adult Children n/a n/a 0 0
 Sibling n/a n/a 2 18
 Cousin n/a n/a 0 0

N = 16 for patients, 11 for caregivers.

*One spouse caregiver conducted individual interviews in writing only, as she is deaf.

Descriptive statistics for all psychological variables among patients are summarized in Table 3. Patients endorsed a mean BDI-II score of 14 (SD = 9.5), suggesting mild mood disturbance. While 40% (n = 12) of respondents did not report depressive symptoms, 26.7% (n = 8) reported mild depressive symptoms, 20% (n = 6) endorsed borderline depressive symptoms, 6.7% (n = 2) reported moderate symptoms, and 6.7% (n = 2) reported severe depression (Fig 1). Overall, 33% (n = 10) of the sample endorsed symptoms suggestive of clinical depression.

Table 3. Descriptive analysis of psychological variables in patients and caregiver samples.

Patients
Mean SD Skewness Kurtosis
Depression (BDI-II) 14.03 9.50 1.35 2.23
Anxiety (BAI) 14.24 9.92 0.88 0.60
Psychological Inflexibility (AAQ-II) 16.60 7.49 1.12 1.53
Cognitive Fusion (CFQ-13) 37.50 13.17 0.10 -0.18
Coping Style
 Undercontrolled 14.17 8.88 0.44 -0.77
 Overcontrolled 29.63 10.71 -0.94 0.45
Childhood Trauma (ACEs) 2.40 2.39 1.05 0.82
Caregivers
Mean SD Skewness Kurtosis
Depression (BDI-II) 7.20 5.92 0.46 -0.66
Anxiety (BAI) 8.10 9.31 1.08 0.03
Psychological Inflexibility (AAQ-II) 11.90 4.84 0.85 0.17
Cognitive Fusion (CFQ-13) 32.10 12.19 -0.22 -1.18
Coping Style
 Undercontrolled 10.71 4.99 1.08 0.23
 Overcontrolled 32.19 9.27 -1.26 0.77
Childhood Trauma (ACEs) 2.00 2.03 0.59 -1.05

N = 30 for patients, 21 for caregivers.

SD = standard deviation

Fig 1. NMOSD patient depressive symptoms endorsed on BDI-II.

Fig 1

Participants endorsed a mean BAI score of 14.2 (SD = 9.9), suggesting mild anxiety. While 27.5% (n = 8) reported minimal anxiety, 31% (n = 9) reported mild anxiety, 31% (n = 9) endorsed moderate anxiety, and 10.5% (n = 3) reported severe anxiety (Fig 2). Overall, 72% (n = 21) of the sample endorsed symptoms suggestive of clinically relevant anxiety.

Fig 2. NMOSD patient anxiety symptoms endorsed on BAI.

Fig 2

The majority of participants endorsed normal levels of psychological flexibility on the AAQ-II (M = 16.6, SD = 7.5), with only 13.3% (n = 4) of the sample scoring in the range of clinically relevant inflexibility. However, most participants (63.3%, n = 19) scored in the clinical range for cognitive fusion on the CFQ-13 (M = 37.5, SD = 13.2), suggesting clinically relevant fusion (i.e., rigid attachment to thoughts as truth). Most participants reported using overcontrolled coping (82.7%, n = 24) on the Styles of Coping Word Pairs, with only 17.3% (n = 5) using undercontrolled coping.

Participants endorsed a variety of values on the VLQ, and reported living according to the following values they rated as important: parenting, work, education, spirituality and community. However, they also endorsed not living according to values which they rated as important, including physical health, recreation/fun, friends/social, marriage, and family.

A minority of patient participants (30%, n = 9) reported a clinically significant history of adverse childhood events on the ACEs (M = 2.4, SD = 2.4, normal range). Adverse childhood experiences endorsed by this sample include: parental divorce (50%, n = 15); abuse: verbal/emotional (33.3%, n = 10), physical (26.7%, n = 8), sexual (20%, n = 6); neglect: emotional (23.3%, n = 7), physical (6.7%, n = 2); household member with: substance abuse (30%, n = 9) mental illness (26.7%, n = 8) imprisoned (16.7%, n = 5); and caregiver physical abuse (6.7%, n = 2).

Bivariate correlational analyses revealed that patients endorsing greater psychological inflexibility also reported significantly higher levels of cognitive fusion (r(28) = .690, p < .001) as well as symptoms of anxiety (r(28) = .553, p = .002) and depression (r(28) = .577, p < .001). Similarly, greater cognitive fusion was significantly associated with increased symptoms of anxiety (r(28) = .510, p = .052) and depression (r(28) = .506, p = .005); however, it was also associated with lower endorsement of an overcontrolled coping style (r(28) = -.388, p = .038). Finally, patients who reported higher levels of anxiety also reported higher levels of depression (r(28) = .555, p = .002). Extent of childhood adverse experiences was not found to be significantly associated with scores on measures of anxiety, depression, psychological inflexibility, cognitive fusion, or coping style.

Most patients (62.2%, n = 23) reported having engaged in talk therapy in the past. However, only 26.9% (n = 7) found this “very helpful” in meeting their needs, with 57.5% (n = 15) finding it only “somewhat helpful” and 15.4% (n = 4) finding it “not helpful at all”. The majority of patients expressed interest in an NMOSD-specific telehealth-delivered talk therapy, with 67.6% (n = 25) expressing definite interest, and 27% (n = 10) indicating they might be interested. Only 5.4% (n = 2) were not interested. When asked if they would like to include their caregiver/loved one in such a treatment, most patients wanted their caregiver involved in some capacity, whether attending some therapy sessions (32.4%, n = 12), all sessions (13.5%, n = 5), or having the caregiver attend separate sessions (21.7%, n = 8). A minority of patients (8.9%, n = 7) did not want their caregiver to attend, or did not have a caregiver (13.5%, n = 5).

Psychometric test data–caregivers

Twenty-one out of 22 caregiver participants completed a demographics survey. One caregiver failed to complete self-report measures. Descriptive statistics for all psychological variables among caregivers are summarized in Table 3. See S1 Data. Caregivers endorsed a mean BDI-II score of 7.2 (SD = 5.9), suggesting no depressive symptoms. While 70% (n = 14) of respondents did not report any depressive symptoms, 25% (n = 5) endorsed mild mood disturbance, and 5% (n = 1) reported borderline depressive symptoms (Fig 3).

Fig 3. Caregiver depressive symptoms endorsed on BDI-II.

Fig 3

Caregivers endorsed a mean BAI score of 8.1 (SD = 9.3), suggesting mild anxiety. While 55% (n = 11) reported minimal anxiety, 25% (n = 5) reported mild anxiety, 15% (n = 3) endorsed moderate anxiety, and 5% (n = 1) reported severe anxiety (Fig 4). Overall, 45% (n = 9) of the sample endorsed symptoms suggestive of clinically relevant anxiety.

Fig 4. Caregiver anxiety symptoms endorsed on BAI.

Fig 4

The vast majority of participants endorsed normal levels of psychological flexibility on the AAQ-II (M = 11.9, SD = 4.8), with only 5% (n = 1) of the sample scoring in the range of clinically relevant inflexibility. Half (n = 10) of all participants scored in the clinical range for cognitive fusion on the CFQ-13 (M = 32.1, SD = 12.2), suggesting clinically relevant fusion. Every caregiver reported using overcontrolled coping (100%, n = 20) on the Styles of Coping Word Pairs.

In the VLQ, caregivers reported living according to the following values they deemed important: physical health, work, family, and community. However, they endorsed not living according to the following values they rated as important: parenting, marriage, and spirituality.

A minority of caregivers (30%, n = 6) reported a clinically significant history of adverse childhood events on the ACEs (M = 2.0, SD = 2.0, normal range). Adverse childhood experiences endorsed by this sample include: parental divorce (28.6%, n = 6); abuse: verbal/emotional (38.1%, n = 8), physical (23.8%, n = 5), sexual (0%); neglect: emotional (23.8%, n = 5), physical (0%); household member with: substance abuse (42.9%, n = 9) mental illness (23.8%, n = 5) imprisoned (9.5%, n = 2); and caregiver physical abuse (9.5%, n = 2).

Bivariate correlations revealed that caregivers who endorsed greater cognitive fusion tended to also report heightened anxiety (r(19) = .450, p = .046) and an overcontrolled coping style (r(19) = .490, p = .028). Also, mirroring patient findings, higher levels of anxiety symptoms were significantly associated with higher endorsement of depressive symptoms (r(19) = .502, p = .024). No other significant associations were found among the caregiver self-report measures.

A significant minority caregivers (47.6%, n = 10) reported having engaged in talk therapy in the past. However, only 3 caregivers found prior therapy “very helpful” in meeting their needs, with 3 finding it only “somewhat helpful” and 2 finding it “not helpful at all”. The majority of caregivers expressed interest in an NMOSD-specific telehealth-delivered talk therapy, with 40% (n = 8) definitely being interested, and 45% (n = 9) indicating they might be interested. Only 15% (n = 3) were not interested. When asked if they would like to include their loved one with NMOSD in such a treatment, most caregivers wanted their patient loved one to attend in some capacity, whether attending some therapy sessions (50%, n = 10), all sessions (30%, n = 6), or having the patient attend separate sessions (10%, n = 2). A minority of caregivers (10%, n = 2) did not want their loved one with NMOSD to attend sessions with them.

No gender differences emerged across any variables in the caregiver sample.

Paired patient-caregiver analyses

Bivariate correlations are summarized in Table 4. Higher patient anxiety was associated with higher caregiver anxiety, and higher level of overcontrolled coping style in patients was associated with higher level of overcontrol in caregivers. Additionally, patient depression scores were associated with lower levels of undercontrol in caregivers, whereas level of undercontrolled coping in patients was associated with higher psychological inflexibility in caregivers.

Table 4. Paired patient-caregiver correlations.

Caregiver Scores
Patient Scores AAQ CFQ BAI BDI UC Coping OC Coping ACE
AAQ .118 -.014 -.041 .191 -.153 -.078 -.068
CFQ .049 -.077 -.140 .052 -.062 -.453^ .304
BAI -.118 .033 .617** .196 .023 -.090 -.152
BDI -.031 -.365 .313 .403^ -.456* -.187 -.056
UC Coping .472* -.142 -.151 .067 .071 -.149 .310
OC Coping .014 -.205 -.353 -.264 .032 .512* -.107
ACE .451^ .217 -.140 .392 -.177 .065 .000

Abbreviations: AAQ, Acceptance and Action Questionnaire-II; CFQ, Cognitive Fusion Questionnaire-13; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory-II; UC, Undercontrolled; OC, Overcontrolled; ACE, Adverse Childhood Experiences.

^ < .1,

* < .05,

** < .01

No other bivariate correlations emerged as significant.

Paired-samples t-tests demonstrated that patients endorsed significantly higher levels of psychological inflexibility (t(18) = 2.111, p = .049), anxiety (t(18) = 3.465, p = .003), and depression (t(18) = 3.229, p = .005) than their caregivers. No significant differences emerged between patients and their caregivers on cognitive fusion, coping style, and adverse childhood experiences. Additionally, patients endorsed larger discrepancies in valued living than their caregivers (t(18) = 2.741, p = .05).

Qualitative data–themes from focus groups and interviews

A variety of themes were conceptualized across patient and caregiver focus groups and interviews, with overall themes described below. Themes from each forum are detailed in four appendices, including sampling of reflective patient and caregiver quotes. See Table 5 for a full list of patient and caregiver themes and selected quotes. See S3 Data.

Table 5. Patient and caregiver themes with selected quotes.

Theme
1. Distrust & lack of respect for medical professionals • “The first time I got sick, I ended up… in the hospital for 5 weeks, 3 different hospitals, ‘cause I was sick for an entire month, and everybody kept sending me home. They kept [saying] we don’t see anything… and sending me home.” (38 y.o. female patient).
• “I had doctors tell me it’s all in my head when I was paralyzed… my respect for doctors has really gone down the drain…” (28 y.o. female patient).
• “‘Oh it’s a pinched nerve, lose ten pounds and you’ll feel better’”(51 y.o. female patient).
2. Lack of support and resources immediately after diagnosis. `“[After I was diagnosed] I went through a whole year of grief. I couldn’t read anything online about NMO. I couldn’t do anything for about seven months after my diagnosis… I felt like I was standing on the edge of a cliff, ready to jump 24/7. My body felt like it was a rubber band stretched to the hundredth degree, and I was just waiting… waiting for another attack” (56 y.o. female patient).
• “My immediate question was, am I going to die from this? I was kind of in like survival mode. It was a fight-or-flight moment. What do I do?” (33 y.o. female patient).
• “Facebook is a huge form of support for information… and that’s very helpful, especially if I’m at an ER and the doctors are not trained on NMO”(35 y.o. female patient).
3. Impact of NMOSD on relationships. • “While she was going to [live-in] blind school,.. all of the others had lost their spouses… the partners couldn’t deal. It strengthened us in the fact that we did this together. I kept the home front down”(49 y.o. male caregiver).
• “Because I look normal, and …have a cane…people walk up to me and they’ll go, ‘Oh what did you do your leg?’ I get so tired of having to say, ‘…I have NMO.’ (52 y.o. female patient).
• “We have family that can’t deal with it… we have cut those ties”(49 y.o. male caregiver).
4. Deviation from valued living. • “That was the saddest thing for me… that we couldn’t go see the Christmas lights as a family anymore because she could no longer see”(74 y.o. female caregiver).
“I just turned 25…you think 25 is the prime of life, and that everything is perfect, and you’re the hottest, … and everything changed. I went from being the kind of person who didn’t even take Tylenol to taking like 18 pills a day. I couldn’t see, I had trouble walking, and my entire life changed overnight… I’m so young, it just doesn’t seem fair”(28 y.o. female patient).
“I started getting really bad anxiety because I couldn’t see people… can’t read facial cues, or… body language. So I got a bunch of anxiety from going blind… I couldn’t really participate in as much things as I used to” (56 y.o. female patient).
5. Internalizing feelings as a coping strategy. • “I am not very expressive about [NMO] unless it really comes to a boiling point where I can’t hide it…I try not to talk about it or make it into a bigger deal than what I think is appropriate” (39 y.o. male patient).
• “I don’t talk about [her NMO]. I just don’t talk about it.” (45 y.o. male caregiver).
• “One of the doctors told me that I needed to prepare for the worst. I just kept my energy high, just to not let her know that I was worried…” (61 y.o. male caregiver).

Theme 1. Distrust and lack of respect for medical professionals

A broad distrust and lack of respect for medical professionals was the most commonly occurring theme across all focus groups and interviews. Many patients (n = 9) and caregivers (n = 7) detailed how this sentiment was catalyzed by long journeys to a proper diagnosis, including misdiagnosis, medical mistreatment that negatively affected course of NMOSD, false prognoses, minimization and undertreatment of pain symptoms, forced reliance on other patients and/or social media for disease education, and caregivers having to assume the role of patient advocate and/or mediator in healthcare settings. Interestingly, all patients who spoke about pain as a primary symptom (n = 6) also reported that their treating providers minimized and undertreated their pain.

Theme 2. Lack of support and resources immediately after diagnosis

Many patients (n = 9) and caregivers (n = 7) reported significant emotional distress immediately following diagnosis of NMOSD, resulting from various factors including isolation as a person with a rare disease and a near-total lack of information provided by medical professionals, resulting in a reliance on other patients (typically via social media) to learn more about the disease. Numerous patients (n = 6) reported trauma symptomology when discussing initial diagnosis of NMOSD, including feelings of being in “survival mode”, hypervigilance for symptoms, sleep disturbance, confusion, and agitation. Patients also reported depressive symptoms during this initial time post-diagnosis, including grief, sadness, anhedonia, feelings of guilt, and suicidal ideation.

Theme 3. The impact of NMOSD on relationships

Patients and caregivers reported significant impact of NMOSD on relationships with friends and loved ones. For some, outward signs of disease had the greatest impact, including mood-related side effects of steroid treatment. For others the “invisible” nature of NMOSD symptoms impacted relationships most, including family members not respecting their limitations as they “look fine”. Some participants (n = 4 patients, n = 4 caregivers) shared the positive impact of NMOSD on their patient-caregiver dyad due to shared feelings of resilience and teamwork.

Theme 4. Deviation from valued living

Identifying personal values and living in accordance with them is a strong predictor of psychological health [41]. Many patient (n = 9) and several caregiver (n = 4) narratives included experiences of NMOSD interfering with their ability to align their personal values with their daily actions. Particularly among younger patients, feelings of an “identity crisis” and difficulty finding meaning in life post-diagnosis were frequently reported experiences. Patients (n = 5) and caregivers (n = 5) reported grief regarding NMOSD symptoms prohibiting the family from participating in favorite activities or traditions. Some caregivers (n = 4) also reported patient’s immunocompromised status impacted their experience of the COVID pandemic, with particular emphasis on being unable to see each other in person for extended periods of time.

Theme 5. Internalizing feelings as a coping strategy

Internalizing or suppressing emotional experience is largely associated with reduced psychological health. Male patients and caregivers in particular, reported relying on internalizing feelings about NMOSD in order to cope with the burden of the disease. Several male patients (n = 2) and caregivers (n = 4) shared sentiments that sharing their feelings about NMOSD would be a negative experience, with caregivers reporting masking feelings of sadness or worry related to their loved one’s NMOSD, to project a sign of strength to their loved ones.

Discussion

Findings from focus groups, individual interviews, and standardized self-report measures, suggest a more complex and nuanced psychological burden among patients with NMOSD and their caregiver/loved ones than that described in empirical literature to date. Nearly three quarters of NMOSD patients and nearly half of their caregivers reported clinically relevant anxiety, which is a higher rate than expected based on literature [11]. The context and source of anxiety, as described by patients and caregivers, commonly centers around the unpredictable nature of subsequent NMOSD attacks, the progressive nature of the disease, and a lack of information about what to expect at the time of diagnosis.

A third of patients endorsed clinically-relevant depressive symptoms, which is similar to that reported in the literature to date. While specific prompts for depression are not reported in the literature to date, patients detailed their grief reactions upon diagnosis, depression regarding deviation from values-based living, and regarding stigma related to having a misunderstood and often “invisible” illness.

A previously unknown aspect of the psychological burden of NMOSD involves cognitive fusion, which can be understood as rigid attachment to thoughts as truth. For example, having the thought “I can’t do anything because of NMOSD” and allowing this thought to prevent oneself from attempting new activities. Most patients and caregivers endorsed clinically-relevant cognitive fusion, with associated high levels of anxiety, suggesting these could be important mental health treatment targets.

The prevalence of over-controlled coping among patients with NMOSD has not been examined to date. The majority of patients and all caregivers reported relying primarily on over-controlled coping styles. Over-controlled coping is associated with rigidity, continued perseverance with ineffective coping skills, internalizing emotions, and distress overtolerance [43]. Patients and caregivers reported persistent stoicism as a coping strategy, including suppressing intense emotions in the presence of their loved ones. Stoicism and overcontrol of emotions, is linked to help-seeking delays, inadequate pain treatment, and caregiver strain [43, 45]. Also, patient and caregiver anxiety and over-controlled coping were strongly associated, suggesting that if one member of the dyad is anxious or inflexible in their approach to managing NMOSD-related stressors, the other member is likely to respond similarly, rather than to provide a calming or flexible counter-perspective.

Another previously unknown aspect of the psychological burden of NMOSD elucidated by this study is the significant stress reaction reported by patients and caregivers immediately following diagnosis. Symptoms reported align with posttraumatic stress disorder (PTSD), including avoiding mention of NMOSD, somatic hypervigilance, and ongoing medical procedures acting as re-traumatization. One respondent experienced sudden onset suicidal ideation at this time. The perception of diagnosis and medical procedures as traumatic is particularly salient given that about a third of patients and caregivers endorsed a clinically significant history of adverse childhood events, including household members living with substance abuse or mental illness, verbal or emotional abuse, and parental divorce. These adverse experiences are associated with increased risk of chronic health conditions, including autoimmune diseases [46].

Factors contributing to this exacerbation of stress include a lack of adequate information about what to expect at the time of diagnosis, total lack of mental health resources at that time, with no follow-up by their care teams regarding emotional health and coping. Almost all patients and caregivers expressed mistrust of medical professionals, as a result of misdiagnosis, minimizing of reported symptoms including pain, iatrogenic treatment, and lack of information as described above. Mistrust toward health care professionals affects patients’ health-related outcomes [47] and is linked to underuse of treatment [48].

Deviation from value-based living is another novel aspect of the psychological burden of NMOSD, reported by both patients and caregivers. Living in accordance with one’s values is a core component of physical and psychological well-being [49], correlating with resilience [50] and medication adherence [51], and negatively correlating with depression [52]. Patients tended to report larger discrepancies between how important a certain valued domain is to them (for example “being an involved grandparent”) and their ability to live according to this value. Both patients and caregivers reported significant stress and grief regarding deviation from living their values since diagnosis of NMOSD. This loss of value-based living was most often caused by physical disabilities, although for some patients, it was also caused by NMOSD-related depression, anxiety, or trauma. Several patients described experiencing an “identity crisis” upon diagnosis. Caregivers reported finding fulfillment in their caregiving role, while also lacking replacement activities and hobbies for those they gave up in order to serve in this role.

Interestingly, impact on social relationships both exacerbated and eased the psychological burden of NMOSD. Patients experiencing outward symptoms of NMOSD, such as vision loss or impaired mobility, reported relationships with friends and family were negatively impacted by the stigma of disability. Patients with “invisible” symptoms of NMOSD, such as pain or nausea, reported their relationships suffered from a lack of understanding of the burden of disease. There is a large body of research detailing the increase in depression and suicide risk associated with diminished social interaction and loss of relationships [53]. Interestingly, most dyads reported their relationship strengthened because of the diagnosis in NMOSD, even as relationships with others were negatively impacted. These dyads reported that a shared sense of resilience and learning to work as a team contributed to a closer relationship.

Finally, most patients and nearly half of their caregivers had a history of engagement in psychotherapy. However, prior psychotherapy experiences were not effective in meeting addressing their needs. An overwhelming majority of patients and caregivers expressed interest in an NMOSD-specific telehealth-delivered talk therapy, specifically as a patient/caregiver dyad.

Limitations

Recruitment via patient advocacy organizations, social media, and word of mouth may have unintentionally recruited participants who are more open to discussing mental health and/or personal experiences. In addition, proof of diagnosis of NMOSD was not required for participation, with self-reported diagnosis (typically accompanied by membership in an NMOSD-specific social media forum) sufficing. Also, despite efforts to include participants with diverse racial and ethnic identities, the majority of our sample was Caucasian, whereas NMOSD is more prevalent among nonwhite populations [6].

Conclusions and future directions

Adjustment to and life with NMOSD poses a unique psychological burden, both to individuals living with this disease, and to their loved ones. Assessment and linkage with mental health services at the time of diagnosis is strongly recommended. Anxiety, depression, cognitive rigidity, over-controlled coping, departure from value-based living, and exacerbated stress reactions were detailed by our sample of people living with NMOSD and their caregivers. Additionally the interconnection between patient and caregiver coping and burden results in anxiety and rigid control strategies for the dyad.

Given the extensive and interconnected psychological burden of NMOSD experienced by patients and their loved ones, and the reported interest in a dyadic intervention, we propose a caregiver-assisted, NMOSD-specific mental health intervention, delivered via telehealth in order to accommodate physical limitations associated with NMOSD. Specifically, Acceptance and Commitment Therapy (ACT) [54], adapted to address the specific psychological burden of NMOSD as outlined in our findings, is one potential intervention. This novel, experiential talk-therapy has proven effective in the management of other illness states [5558]. With an emphasis on values clarification, taking steps toward personal values despite illness-related obstacles, un-sticking from problematic thought content, and acceptance of what can not be changed, ACT, adapted for NMOSD, has high potential to reduce depression, stress, and caregiver strain, and improve treatment adherence and quality of life.

Additionally, we propose that immediate attention be devoted to repairing the distrust that many patients with NMOSD and their caregivers have toward the medical system, often due to misdiagnosis and resulting iatrogenic treatment. Given newer testing and diagnostic protocols, hopefully a new generation of patients with NMOSD will not endure such a “diagnostic odyssey”. In the meantime, establishment of a vetted, centralized location for detailed patient education and resource materials, including linkage with effective mental health support is needed urgently, and should be shared at the time of diagnosis. In addition, further education of providers is required, regarding the specific psychological burden of NMOSD, including anxiety regarding subsequent attacks and progression, a tendency toward stoicism despite pain, anxiety, and depression, and the need to support and involve the caregiver to prevent burnout and enhance the patient-caregiver support system.

Supporting information

S1 Data

(XLSX)

pone.0300777.s001.xlsx (25.2KB, xlsx)
S2 Data

(XLSX)

pone.0300777.s002.xlsx (35.7KB, xlsx)
S3 Data. Patient focus group qualitative data.

(DOCX)

pone.0300777.s003.docx (41.6KB, docx)

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

CVO'H, DCE, NKC, CNN received an award (awarded to CVO'H as the PI) from Alexion Pharmaceuticals to fund this study (alexion.com). While the funders had no role in study design, data collection & analysis, decision to publish, or preparation of the manuscript - they were given 30 days in which to review the manuscript prior to publication.

References

  • 1.Prain K, Woodhall M, Vincent A, Ramanathan S, Barnett MH, Bundell CS, et al. AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD. Front Neurol. 2019;10. doi: 10.3389/fneur.2019.01028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–89. doi: 10.1212/WNL.0000000000001729 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol. 2014;10(9):493–506. doi: 10.1038/nrneurol.2014.141 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Sato DK, Lana-Peixoto MA, Fujihara K, de Seze J. Clinical Spectrum and Treatment of Neuromyelitis Optica Spectrum Disorders: Evolution and Current Status. Brain pathol. 2013;23(6):647–60. doi: 10.1111/bpa.12087 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.De Seze J, Kremer L, Collongues N. Neuromyelitis optica spectrum disorder (NMOSD): A new concept. Rev neurol. 2016;172(4–5):256–62. doi: 10.1016/j.neurol.2016.03.003 [DOI] [PubMed] [Google Scholar]
  • 6.Flanagan EP, Cabre P, Weinshenker BG, Sauver JS, Jacobson DJ, Majed M, et al. Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrum. Ann neurol. 2016;79(5):775–83. doi: 10.1002/ana.24617 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Ayzenberg I, Richter D, Henke E, Asseyer S, Paul F, Trebst C, et al. Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder: A Cross-Sectional Study of 166 AQP4 Antibody–Seropositive Patients. Neurol neuroimmunol neuroinflamm. 2021;8(3):e985. doi: 10.1212/NXI.0000000000000985 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Chavarro VS, Mealy MA, Simpson A, Lacheta A, Pache F, Ruprecht K, et al. Insufficient Treatment of Severe Depression in Neuromyelitis Optica Spectrum Disorder. Neurol neuroimmunol neuroinflamm. 2016;3(6). doi: 10.1212/NXI.0000000000000286 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Fernandez V, Alonso N, Melamud L, Villa A. Psychiatric comorbidities and suicidality among patients with neuromyelitis optica spectrum disorders in Argentina. Mult Scler Relat Disord. 2018;19:40–3. doi: 10.1016/j.msard.2017.11.002 [DOI] [PubMed] [Google Scholar]
  • 10.Meca-Lallana JE, Gómez-Ballesteros R, Pérez-Miralles F, Forero L, Sepúlveda M, Calles C, et al. Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients’ Perspective: An Observational Cross-Sectional Study. Neurol Ther. 2022;11(3):1101–16. doi: 10.1007/s40120-022-00356-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Ebadi Z, Saeedi R, Hashemi SN, Gheini MR, Sahraian MA, Moghadasi AN. Evaluation of types of psychological disorders in patients with neuromyelitis optica spectrum disorder (NMOSD). Mult Scler Relat Disord. 2020;42:102128. doi: 10.1016/j.msard.2020.102128 [DOI] [PubMed] [Google Scholar]
  • 12.Miao X, Shi Z, Chen H, Zhou H, Yang R. The impact of pain, anxiety and depression on sleep quality in Chinese patients with neuromyelitis optica spectrum disorders. Neurol Asia. 2017;22(3). [Google Scholar]
  • 13.Shi Z, Chen H, Lian Z, Liu J, Feng H, Zhou H. Factors that impact health-related quality of life in neuromyelitis optica spectrum disorder: anxiety, disability, fatigue and depression. J Neuroimmunol. 2016;293:54–8. doi: 10.1016/j.jneuroim.2016.02.011 [DOI] [PubMed] [Google Scholar]
  • 14.Akaishi T, Nakashima I, Misu T, Fujihara K, Aoki M. Depressive state and chronic fatigue in multiple sclerosis and neuromyelitis optica. J Neuroimmunol. 2015;283:70–3. doi: 10.1016/j.jneuroim.2015.05.007 [DOI] [PubMed] [Google Scholar]
  • 15.Seok JM, Choi M, Cho EB, Lee HL, Kim BJ, Lee KH, et al. Fatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life. PLoS ONE. 2017;12(5):e0177230. doi: 10.1371/journal.pone.0177230 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Beekman J, Keisler A, Pedraza O, Haramura M, Gianella-Borradori A, Katz E, et al. Neuromyelitis optica spectrum disorder: patient experience and quality of life. Neurol neuroimmunol neuroinflamm. 2019;6(4). doi: 10.1212/NXI.0000000000000580 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Asseyer S, Cooper G, Paul F. Pain in NMOSD and MOGAD: a systematic literature review of pathophysiology, symptoms, and current treatment strategies. Front Neurol. 2020;11:778. doi: 10.3389/fneur.2020.00778 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Fujihara K, Hattori S, Kleiter I, Levy M, Matsuda Y, Mitsutake A, et al. Patient-reported burden of symptoms in neuromyelitis optica: A secondary analysis on pain and quality of life. J Neurol Sci. 2021;428:117546. doi: 10.1016/j.jns.2021.117546 [DOI] [PubMed] [Google Scholar]
  • 19.Mirmosayyeb O, Barzegar M, Nafari A, Mahdi Hosseinabadi A, Malekzadeh A, Ghasemi M, et al. Sexual dysfunction in women with neuromyelitis optica spectrum disorders and multiple sclerosis. Sex Disabi. 2022;40(2):381–92. [Google Scholar]
  • 20.Zhang Y, Zhang Q, Shi Z, Chen H, Wang J, Yan C, et al. Sexual dysfunction in patients with neuromyelitis optica spectrum disorder. J Neuroimmunol. 2020;338:577093. doi: 10.1016/j.jneuroim.2019.577093 [DOI] [PubMed] [Google Scholar]
  • 21.Meca-Lallana JE, Prefasi D, Pérez-Miralles F, Forero L, Sepúlveda M, Calles C, et al. Perception of stigma in patients with neuromyelitis optica spectrum disorder. Patient Prefer Adherence. 2021:713–9. doi: 10.2147/PPA.S305707 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Hollinger KR, Franke C, Arenivas A, Woods SR, Mealy MA, Levy M, et al. Cognition, mood, and purpose in life in neuromyelitis optica spectrum disorder. J Neurol Sci. 2016;362:85–90. doi: 10.1016/j.jns.2016.01.010 [DOI] [PubMed] [Google Scholar]
  • 23.Mutch K, Methley A, Hamid S, Moore P, Jacob A. If they are OK, we are OK: the experience of partners living with neuromyelitis optica. Disabil Rehabil. 2017;39(13):1279–86. doi: 10.1080/09638288.2016.1193233 [DOI] [PubMed] [Google Scholar]
  • 24.aloe_watermelon. Talking my wife off the ledge. NMO Disease. Reddit. 2022.
  • 25.Barton C. My Journey With Neuromyelitis Optica Spectrum Disorder. 2022. Available from: https://themighty.com/topic/neuromyelitis-optica/my-journey-with-neuromyelitis-optica-spectrum-disorder. [Google Scholar]
  • 26.Angela’s NMO Story—From Managing Retail to Managing Vision Loss & Paralysis. 2017. Available from: https://www.sumairafoundation.org/angelas-nmo-story-managing-retail-managing-vision-loss-paralysis/.
  • 27.Douglas C. Never Stop Advocating for Yourself With NMOSD. The Mighty. 2022. [Google Scholar]
  • 28.Zinger T. ’This is Not MS’—how four words changed my life with a rare disease. The Mighty. 2022. [Google Scholar]
  • 29.Megan’s NMO Story—Your Average Girl Living in a Chronic Illness World. 2020. Available from: https://www.sumairafoundation.org/megans-nmo-story-your-average-girl-living-in-a-chronic-illness-world/.
  • 30.Adam’s NMO Story–Narrated by the Love of his Life. 2020. Available from: https://www.sumairafoundation.org/adamnmo/
  • 31.Radiate Positivity Ableism and discrimination. Neuromyelitis Optica. 2022.
  • 32.Wall S. What you can’t see behind my smile as someone with chronic pain. The Mighty 2020. [Google Scholar]
  • 33.Bierer BE, White SA, Gelinas L, Strauss DH. Fair payment and just benefits to enhance diversity in clinical research. J Clin Transl Sci. 2021;5(1):e159. doi: 10.1017/cts.2021.816 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Grady C. Payment of clinical research subjects. J Clin Invest. 2005;115(7):1681–7. doi: 10.1172/JCI25694 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Pandya M, Desai C. Compensation in clinical research: The debate continues. Perspect Clin Res. 2013;4(1):70–4.37. doi: 10.4103/2229-3485.106394 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Mateen FJ, Trápaga Hacker CM. Understanding the employment impact of neuromyelitis optica spectrum disorder in the USA: Mixed methods. Front Neurol. 2023;14:1142640. doi: 10.3389/fneur.2023.1142640 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Beck AT, Epstein N, Brown G, Steer R. Beck anxiety inventory. J Consult Clin Psychol. 1993. [DOI] [PubMed] [Google Scholar]
  • 38.Beck AT, Steer RA, Brown G. Manual for the Beck depression inventory–II. Clin Psychol Rev. 1996. [Google Scholar]
  • 39.Gillanders DT, Bolderston H, Bond FW, Dempster M, Flaxman PE, Campbell L, et al. The development and initial validation of the cognitive fusion questionnaire. Behav Ther. 2014;45(1):83–101. doi: 10.1016/j.beth.2013.09.001 [DOI] [PubMed] [Google Scholar]
  • 40.Bond FW, Hayes SC, Baer RA, Carpenter KM, Guenole N, Orcutt HK, et al. Preliminary psychometric properties of the Acceptance and Action Questionnaire–II: A revised measure of psychological inflexibility and experiential avoidance. Behav Ther. 2011;42(4):676–88. doi: 10.1016/j.beth.2011.03.007 [DOI] [PubMed] [Google Scholar]
  • 41.Wilson KG, Groom J. The Valued Living Questionnaire. 2002. Available from Kelly Wilson. [Google Scholar]
  • 42.Murphy A, Steele H, Steele M, Allman B, Kastner T, Dube SR. The clinical Adverse Childhood Experiences (ACEs) questionnaire: Implications for trauma-informed behavioral healthcare. Integrated early childhood behavioral health in primary care: A guide to implementation and evaluation. 2016:7–16. [Google Scholar]
  • 43.Lynch TR. Radically open dialectical behavior therapy: Theory and practice for treating disorders of overcontrol: New Harbinger Publications; 2018. [Google Scholar]
  • 44.Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101. [Google Scholar]
  • 45.Pathak EB, Wieten SE, Wheldon CW. Stoic beliefs and health: development and preliminary validation of the Pathak-Wieten Stoicism Ideology Scale. BMJ open. 2017;7(11):e015137. doi: 10.1136/bmjopen-2016-015137 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Dube SR, Fairweather D, Pearson WS, Felitti VJ, Anda RF, Croft JB. Cumulative childhood stress and autoimmune diseases in adults. Psychosom Med. 2009;71(2):243. doi: 10.1097/PSY.0b013e3181907888 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Cuevas AG, O’Brien K, Saha S. Can patient-centered communication reduce the effects of medical mistrust on patients’ decision making? Health Psychol. 2019;38(4):325–33. doi: 10.1037/hea0000721 [DOI] [PubMed] [Google Scholar]
  • 48.Rosser BA, McCracken LM, Velleman SC, Boichat C, Eccleston C. Concerns about medication and medication adherence in patients with chronic pain recruited from general practice. Pain. 2011;152(5):1201–5. doi: 10.1016/j.pain.2011.01.053 [DOI] [PubMed] [Google Scholar]
  • 49.Finkelstein-Fox L, Pavlacic JM, Buchanan EM, Schulenberg SE, Park CL. Valued living in daily experience: Relations with mindfulness, meaning, psychological flexibility, and stressors. Cognit Ther Res. 2020;44(2):300–10. [Google Scholar]
  • 50.Ceary CD, Donahue JJ, Shaffer K. The strength of pursuing your values: Valued living as a path to resilience among college students. Stress and health. 2019;35(4):532–41. doi: 10.1002/smi.2886 [DOI] [PubMed] [Google Scholar]
  • 51.Gaudiano BA, Wenze SJ, Weinstock LM, Tezanos KM, Miller IW. Valued living and its relationship to medication adherence in patients with bipolar and comorbid substance use disorders. J Nerv Ment Dis. 2017;205(3):178–81. doi: 10.1097/NMD.0000000000000533 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Bramwell K, Richardson T. Improvements in depression and mental health after acceptance and commitment therapy are related to changes in defusion and values-based action. J Contemp Psychother. 2017;48:9–14. doi: 10.1007/s10879-017-9367-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Center for Disease Control and Prevention. Risk and Protective Factors. 2021.
  • 54.Hayes SC. Acceptance and commitment therapy, relational frame theory, and the third wave of behavioral and cognitive therapies. Behav Ther. 2004;35(4):639–65. [DOI] [PubMed] [Google Scholar]
  • 55.González-Fernández S, Fernández-Rodríguez C. Acceptance and commitment therapy in cancer: review of applications and findings. Behav Med. 2019;45(3):255–69. doi: 10.1080/08964289.2018.1452713 [DOI] [PubMed] [Google Scholar]
  • 56.Harrison AM, McCracken LM, Jones K, Norton S, Moss-Morris R. Using mixed methods case-series evaluation in the development of a guided self-management hybrid CBT and ACT intervention for multiple sclerosis pain. Disabil Rehabil. 2017;39(18):1785–98. doi: 10.1080/09638288.2016.1209580 [DOI] [PubMed] [Google Scholar]
  • 57.O’Hayer CV, O’Loughlin CM, Nurse CN, Smith PJ, Stephen MJ. ACT with CF: a telehealth and in-person feasibility study to address anxiety and depressive symptoms among people with cystic fibrosis. J Cyst Fibros. 2021;20(1):133–9. doi: 10.1016/j.jcf.2020.11.013 [DOI] [PubMed] [Google Scholar]
  • 58.Sahebari M, Ebrahimabad MJA, Shoraketokanlo AA, Sharbaf HA, Khodashahi M. Efficacy of acceptance and commitment therapy in reducing disappointment, psychological distress, and psychasthenia among systemic lupus erythematosus (SLE) patients. Iran J Psychiatry. 2019;14(2):130–6. [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Teresa Juárez-Cedillo

20 Sep 2023

PONE-D-23-06896The Psychological Burden of NMOSD - As Defined by Patients and CaregiversPLOS ONE

Dear Dr. o'hayer,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 04 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Teresa Juárez-Cedillo, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“This study generously was supported by a grant from Alexion AstraZeneca Rare Disease.”

We note that you have provided additional information within the Acknowledgements Section that is not currently declared in your Funding Statement. Please note that funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“CVO'H, DCE, NKC, CNN received an award (awarded to CVO'H as the PI) from Alexion Pharmaceuticals to fund this study (alexion.com). While the funders had no role in study design, data collection & analysis, decision to publish, or preparation of the manuscript - they were given 30 days in which to review the manuscript prior to publication.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well.

Additional Editor Comments (if provided):

It is a relevant study since it considers the perspective of both patients and their caregivers, however, there are some points that must be considered before being able to make a decision.

The introduction should be focused on the psychological burden of NMOSD and the main findings found so far.

Authors must define whether they will only include qualitative data or also quantitative data in the writing.

If they only include quantitative data think that is the objective of the study).

Adequately describe the methodology, the population selection criteria, as well as the qualitative methodology technique used to obtain the sample size.

In the analysis section, clearly describe the type of analysis carried out on the data obtained (what theory was the analysis based on), as well as the software used for the analysis.

Choose the testimonies of the participants based on their relevance to respond to the objective of the study.

Carry out the discussion based on these findings identified in the testimonies in accordance with the theory chosen for their analysis.

Review references that comply with the requirements of the journal https://journals.plos.org/plosone/s/submission-guidelines

If, on the other hand, it is decided to use both quantitative and qualitative data, it is necessary to restructure the writing based on a mixed study and substantiate both the methodology and the data analysis.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This paper describes the psychological burden of NMOSD in patients and caregivers. Alot of work has clearly gone into this. The manuscript is detailed with good insights and clear themes, and provides viewpoints from both patient and caregiver perspective (although having the physician perspective would have provided another source of triangulation).

In particular, I like how many critiques of the healthcare system were raised, and this honesty highlights also the trust participants had in the research team, to be able to freely share their comments.

Some major comments

The paper is excessively lengthy throughout, especially the introduction, results and discussion. Although there is no word limit imposed by the journal, such a length is cognitively draining. Most other qualitative articles published in PLOS ONE look to be about 2500-3500 words.

Secondly, the overall aims of the study are not clearly demonstrated – what is the clinical question and what are the gaps that the study is trying to address?

Other comments

In the abstract, it can be clearer that the 16 patients and 11 caregivers who did semi-structured interviews were a subset of the 31 adults/22 caregivers (if indeed so)

I feel that the introduction is too long. Given that the paper focuses on the psychological burden of NMOSD, I find that the section detailing the factors that contribute to the debilitating nature of NMOSD (page 4-7) may be unnecessary

Given that the psychological burden of NMOSD is fairly well established as authors alluded to, what is the purpose of the current study, e.g gaps in current literature and how the study aims to address these gaps can be better detailed.

The methodology could be more clearly fleshed out.

- Were the individual interviews concurrent or sequential to the focused group interviews?

- Was there any exclusion criteria?

Additionally, important elements of a rigorous qualitative study (memo writing, participant checking, iterative analysis, theoretical saturation, coreq checklist etc) appear to be missing

“All 30 patient participants completed a demographics survey. “

- 30 or 31?

Results started off with quantitative analyses of 30 patient survey responses, followed by 21 caregiver surveys. I personally dont think this should be the main focus of the manuscript as the sample is quite small. Furthermore, many of the statistical analyses appeared to have been conducted without a clear hypothesis.

I’m quite confused with the analysis of qualitative data. The way it is written on page 22 seems to suggests that qualitative thematic analysis was only conducted for those who did the individual interviews (16 patients and 11 caregivers)

The results would be better represented as a table of themes with select highlighted quotes (with a full table as a supplementary file). Within the manuscript text itself, writing should be more concise and quotes can be shortened. - Instead of quoting full quotes from patients, a better way would be to pick out portions of the sentence which they specifically demonstrate the theme – for e.g. page 21 under point 4.1 – the first quote could go without the portion regarding the nurses.

Alot of the discussion section reiterates and repeats findings from the results. It may be better to discuss instead what is new and how the results build on existing literature.

Furthermore, given that there were so much negative comments toward healthcare providers, how do authors think the healthcare system could be improved to provide a better experience for NMOSD patients?

I do like the section on future directions which provide practical suggestions for implementation, although like the rest of the manuscript, this could be more concisely expressed.

Reviewer #2: EVALUATION

Thank you for the opportunity to review this paper exploring the Psychological Burden of NMOSD - As Defined by Patients and Caregivers. The study makes some unique contributions to literature, although I have major concerns with the paper in its current format that will need to be addressed prior to being considered for publication. The primary concerns are the following:

1. The manuscript did not follow submission guidelines as detailed on the Plos One website (https://journals.plos.org/plosone/s/submission-guidelines). It should be organized following Plos One formatting and lines of the manuscript should be also numbered to make review easy.

2. The authors collected qualitative and quantitative data, and this means that they employed a mixed methods approach. However, in the methods section, they are not clear about an employed research design, the sampling strategies for both quantitative and qualitative data, and the procedures of data collection, analysis, and discussion. You can refer to the suggested book from 203 pages to improve your manuscript.

TITLE

3. The study mixed qualitative and quantitative data. However, this is not quickly identified by the title.

ABSTRACT

4. The abstract does not make it clear what the rationale of the study is and why collecting both qualitative data and quantitative data. What did the qualitative study provide that the quantitative study did not and vice-versa? How does it add value?

5. “This study aims to describe and understand the psychological burden of patients with NMOSD and their caregiver/loved ones via self-report measures, focus groups, and in-depth interviews”. I propose: This study aims to investigate and understand the psychological burden of patients with NMOSD and their caregivers/loved ones from…………

6. Research design, population, sampling techniques, sample, study instruments, estimation techniques, and software for data storage and analysis should also be highlighted in the abstract.

INTRODUCTION

7. The authors should describe variables in chronological and logical sequences rather than creating their subheadings with a lack between them.

8. Also, the authors should be clear on the rationale for the study. It is not enough to say “empirical literature and patient media perspectives suggest a significant psychological burden associated with diagnosis of NMOSD. There is a clear need to develop a comprehensive understanding of this experience, both from patient and caregiver perspectives.” It would be helpful if the introduction reviewed some of the existing literature on the Psychological Burden of NMOSD among Patients and their Caregivers by highlighting at the same time the existing gap that led to collecting qualitative and quantitative data.

METHODS

9. In the participants' section, please incorporate the research design, population, sampling techniques, sample (also summary statistics describing the sample), inclusion, and exclusion criteria where applicable.

10. Also, include statistics and software for data storage and analysis in the statistical analysis part.

11. It is not clear why using individual interviews and focus groups to collect qualitative data

12. The authors stated, “Both patient and caregiver participants were compensated via $150 gift card for completion of self-report measures and participation in an individual interview.” However, they should provide ethically accepted reasons for providing this amount and the reference supporting their reason.

13. Authors should report the value of Cronbach’s alpha of the study instruments as well as their cutoff scores to easily classify the participants into those with significant symptoms of psychological burden and those without significant symptoms.

RESULTS

14. I think tables can help present clearly and summarise the authors’ findings. Why didn’t you use the tables?

DISCUSSION

15. The referencing style should be Elsevier Vancouver

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Ellie Choi

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: The review.docx

pone.0300777.s004.docx (13.2KB, docx)
PLoS One. 2024 Mar 29;19(3):e0300777. doi: 10.1371/journal.pone.0300777.r002

Author response to Decision Letter 0


23 Jan 2024

Please see attached "response to reviewers" document.

Decision Letter 1

Teresa Juárez-Cedillo

27 Feb 2024

PONE-D-23-06896R1The psychological burden of NMOSD – a mixed method study of patients and caregiversPLOS ONE

Dear Dr. o'hayer,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR:

Minor revisions are required. Reviewing the length of the introduction focusing on considering the most relevant elements reported in the literature.

All data analyzed from the study population must be in the results section.

Combine the conclusion with the discussion and write a new conclusion with the most relevant findings of this study.

The authors must consider the observations made by the reviewers.

==============================

Please submit your revised manuscript by Apr 12 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Teresa Juárez-Cedillo, PhD

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Unfortunately I cant seem to access the author's reply to the previous comments.

For the current manuscript, the front component/introduction is quite lengthy and difficult to get through. I'm not sure there is a need to go through paragraphs of each individual construct and the existing literature (e.g. coping, psychological resilience). I feel that it is more important to synthesise the literature to highlight the gaps in knowledge.

I'm not sure what happened to the tables/figures, have they been removed from the previous version?

Reviewer #2: Thank you for allowing me to read this revised manuscript. Having reread the manuscript, the authors have addressed most of my comments. However, there are a few comments to address before heading to another step.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Comments.docx

pone.0300777.s005.docx (15KB, docx)
PLoS One. 2024 Mar 29;19(3):e0300777. doi: 10.1371/journal.pone.0300777.r004

Author response to Decision Letter 1


4 Mar 2024

Dear Dr. Juárez-Cedillo,

Thank you for the detailed feedback regarding our manuscript, “The psychological burden of NMOSD – a mixed method study of patients and caregivers” (PONE-D-23-06896R1). We are aware of the considerable amount of time and effort that go into reviewing a manuscript, and we are very appreciative of the attention to our work and the thoughtful suggestions made.

Below are our responses to the reviewer comments. We are confident that a more concise and focused manuscript results from the reviewer’s thoughtful feedback.

ACADEMIC EDITOR:

COMMENT 1: Reviewing the length of the introduction focusing on considering the most relevant elements reported in the literature.

RESPONSE TO COMMENT #1: Thank you – we have condensed the introduction considerably, focusing only on

COMMENT 2: All data analyzed from the study population must be in the results section.

RESPONSE TO COMMENT #2: Yes – these are now all included in the results section.

COMMENT 3: Combine the conclusion with the discussion and write a new conclusion with the most relevant findings of this study.

RESPONSE TO COMMENT #3: Thank you – we have created a new Conclusions and Future Directions section to address this feedback.

Reviewer #1:

COMMENT 1: The front component/introduction is quite lengthy and difficult to get through. I'm not sure there is a need to go through paragraphs of each individual construct and the existing literature (e.g. coping, psychological resilience). I feel that it is more important to synthesise the literature to highlight the gaps in knowledge.

RESPONSE TO COMMENT #1: Agree – we have condensed the intro considerably.

Reviewer #2:

COMMENT 1: Page 4-5: Generally, paragraphs are five to ten lines in length. A paragraph of two to four lines doesn’t look smart.

RESPONSE TO COMMENT #1: Agree – we have consolidated paragraphs in the newly revised and condensed introduction.

COMMENT 2: Pages 7-8: Socio-demographic characteristics of the participants should be removed from the materials and methods section to be pasted and analyzed in the results section.

RESPONSE TO COMMENT #2: Thank you for this correction, we have moved this information and associated Tables 1 and 2 accordingly, to the results section.

COMMENT 3: Pages 14-18: Information regarding descriptive analysis of study variables and the rate of psychological burden was clearly mentioned in the manuscript. However, there are no tables summarizing this information.

RESPONSE TO COMMENT #3: Thank you – we have created such a table summarizing the descriptive analysis of study variables. This is now Table 3.

COMMENT 4: Also, can you provide information on other measurements of variability such as standard deviation, skewness, and kurtosis? Descriptive analysis of study variables based only on the mean doesn’t provide much information.

RESPONSE TO COMMENT #4: Yes, agree - we have included these measures of variability (standard deviation, skewness and kurtosis) in our new Table 3.

COMMENT 5: Pages 22-25: It seems that your conclusion section reflects the discussion section. The reason is that you have explained what you found, showing how it correlates with the existing literature, which makes it a discussion section. Consequently, you can then set up a conclusion section apart to summarize your findings and explain why they are very important. Then, I suggest the following sections: Results, Discussion, Conclusions,…

RESPONSE TO COMMENT #5: Thank you for this suggestion. We have now differentiated Results from Discussion sections and, rather than creating much additional text, we have created an integrated Conclusions and Future Directions section.

We have electronically submitted the revised manuscript. We hope that we have addressed all comments and suggestions appropriately. If not, we will be happy to consider making whatever additional changes you or the reviewers request. Thank you for continuing to consider this manuscript for publication in PLOS ONE. We look forward to hearing from you.

Sincerely,

C. Virginia O’Hayer, Ph.D.

Clinical Professor

Director, Jefferson Center City Clinic for Behavioral Medicine

Department of Psychiatry & Human Behavior

Thomas Jefferson University Hospital

Attachment

Submitted filename: Response to Reviewers 2nd revision.docx

pone.0300777.s006.docx (33.1KB, docx)

Decision Letter 2

Teresa Juárez-Cedillo

6 Mar 2024

The psychological burden of NMOSD – a mixed method study of patients and caregivers

PONE-D-23-06896R2

Dear Dr. o'hayer,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at http://www.editorialmanager.com/pone/ and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Teresa Juárez-Cedillo, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Teresa Juárez-Cedillo

19 Mar 2024

PONE-D-23-06896R2

PLOS ONE

Dear Dr. o'hayer,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Teresa Juárez-Cedillo

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Data

    (XLSX)

    pone.0300777.s001.xlsx (25.2KB, xlsx)
    S2 Data

    (XLSX)

    pone.0300777.s002.xlsx (35.7KB, xlsx)
    S3 Data. Patient focus group qualitative data.

    (DOCX)

    pone.0300777.s003.docx (41.6KB, docx)
    Attachment

    Submitted filename: The review.docx

    pone.0300777.s004.docx (13.2KB, docx)
    Attachment

    Submitted filename: Comments.docx

    pone.0300777.s005.docx (15KB, docx)
    Attachment

    Submitted filename: Response to Reviewers 2nd revision.docx

    pone.0300777.s006.docx (33.1KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES